vulvovaginal candidiasis – Page 2

Molecular Identification of Candida Species among Iranian Patients: Pursuing Candida auris

mycolabadmin

This study evaluated a simple molecular test called PCR-RFLP to identify different types of Candida fungi in hospitalized patients in Iran. Among 136 patient samples, researchers found eight different Candida species, with common Candida albicans being most prevalent, but other more dangerous species also present. No cases of the emerging pathogen Candida auris were found, though the test method can effectively detect it. The researchers conclude this cost-effective test could be valuable for identifying dangerous fungal infections in developing countries.

Synergistic potential and apoptosis induction of Bunium persicum essential oil and its pure components, cuminaldehyde and γ-terpinene, in combination with fluconazole on Candida albicans isolates: in vitro and in silico evaluation

mycolabadmin

Researchers studied how an essential oil from black cumin seeds (Bunium persicum) and two of its key active components could work together with the antifungal drug fluconazole to fight Candida albicans infections, including drug-resistant strains. Using laboratory tests and computer modeling, they found that cuminaldehyde, one of the main components, was particularly effective when combined with fluconazole, killing yeast cells through multiple mechanisms. This suggests that natural plant compounds could be valuable partners with conventional antifungal medications to overcome drug resistance.

Synergistic potential and apoptosis induction of Bunium persicum essential oil and its pure components, cuminaldehyde and γ-terpinene, in combination with fluconazole on Candida albicans isolates: in vitro and in silico evaluation

mycolabadmin

Researchers tested how Bunium persicum essential oil and its components work alongside the antifungal drug fluconazole against Candida albicans infections. Cuminaldehyde, a major component of the oil, showed the strongest effects when combined with fluconazole, making infection-causing cells die faster than each substance alone. This combination approach could help overcome drug-resistant fungal infections and offers a promising natural alternative to synthetic drugs alone.

Genomic Insights of Candida krusei, an Emerging Fungal Pathogen With Intrinsic Antifungal Resistance

mycolabadmin

Candida krusei is a yeast that causes serious bloodstream infections, particularly in people with weakened immune systems. Unlike many other fungi, it naturally resists common antifungal drugs like fluconazole, making infections hard to treat. The organism can form protective biofilms and has multiple genetic mechanisms that help it survive antifungal treatment. Researchers are exploring new drugs and treatment strategies to combat this growing health threat, especially in hospitals.

New insights toward personalized therapies for vulvovaginal candidiasis and vaginal co-infections

mycolabadmin

Vaginal yeast infections (vulvovaginal candidiasis) and bacterial vaginosis are very common conditions affecting millions of women worldwide. Current treatments often fail or lead to antibiotic resistance. This review explores new personalized approaches including zinc supplementation, specific probiotics, and immune-boosting therapies that are tailored to each woman’s unique vaginal environment to prevent recurring infections.

Investigating the Increasing Azole Resistance in Candida Infections Among Critically Ill Patients: Experience From a Tertiary-Level Setup in North India

mycolabadmin

This study tracked the increase in drug-resistant yeast infections in hospitalized patients in India from 2023 to 2025. The researchers found that common antifungal medications like fluconazole are becoming less effective, with resistance rates nearly doubling over the study period. The good news is that newer antifungal drugs called echinocandins remained highly effective. The findings highlight the need for better infection control measures and more careful use of antifungal medications.

Invasive Candidiasis in Contexts of Armed Conflict, High Violence, and Forced Displacement in Latin America and the Caribbean (2005–2025)

mycolabadmin

Invasive candidiasis, a serious fungal blood infection caused by Candida species, is a major health crisis in Latin America and the Caribbean with death rates reaching 60% in vulnerable populations. The disease is worsening in areas affected by armed conflict, violence, and displacement where poor living conditions, overcrowding, malnutrition, and lack of healthcare create ideal conditions for the infection to develop and spread. Antifungal drugs are often unavailable or too expensive, and drug-resistant strains of Candida are becoming increasingly common, making treatment extremely challenging in these regions.

Abundant Yet Aberrant T Helper Cell Responses to Candida albicans Underlie Mucosal Candidiasis in Humans and Mice

mycolabadmin

Researchers studied how the immune system fights Candida albicans fungal infections. They found that a specific type of immune cell called Th17 cells is absolutely essential for controlling these infections, while other immune cells called Th2 cells actually make infections worse by blocking the protective Th17 cells. Patients with certain genetic mutations that affect how their immune system works have too many Th2 cells and not enough Th17 cells, making them vulnerable to chronic fungal infections. The study suggests that blocking a molecule called IL-4 could help restore the balance and improve patient outcomes.

Renaming Candida glabrata—A case of taxonomic purity over clinical and public health pragmatism

mycolabadmin

Candida glabrata is a common yeast infection that causes serious illnesses in humans, affecting millions of people worldwide. Scientists have recently proposed renaming it to Nakaseomyces glabrata for technical taxonomic reasons. However, this article argues against the change because it would create confusion for doctors, complicate treatment instructions on medications, disrupt disease tracking systems, and make it harder for patients to understand their conditions. Keeping the familiar name Candida glabrata is more practical and helpful for patient care and public health than strict adherence to taxonomic classification rules.

Exploring the Antifungal Potential of Lawsone-Loaded Mesoporous Silica Nanoparticles Against Candida albicans and Candida glabrata: Growth Inhibition and Biofilm Disruption

mycolabadmin

Researchers developed a new antifungal treatment by loading lawsone (a compound from henna plants) into tiny particles called mesoporous silica nanoparticles. When tested against common fungal infections caused by Candida bacteria, this nano-formulation was more effective than lawsone alone at killing the fungi and breaking down protective biofilm structures. The treatment showed no harm to normal human cells, suggesting it could be a promising natural alternative to treat stubborn fungal infections that resist current antifungal drugs.

Disease: vulvovaginal candidiasis